Dimerix (ASX:DXB) partnered with the UK's National Registry of Rare Kidney Diseases to identify patients for the Action3 phase 3 clinical trial, according to a Monday filing with the Australian bourse.
The trial aims to assess the efficacy and safety of the biopharmaceutical company's DMX-200 in treating a rare kidney condition called Focal Segmental Glomerulosclerosis, the filing stated. Recruitment is being done across 16 of the 19 planned countries, with a total recruitment target of 286 patients.
Additionally, Dimerix received approval for its Investigational New Drug Application from the Thai Food and Drug Administration, clearing a prerequisite for trial initiation. It expects clinical sites to begin recruitment in Thailand in the coming weeks.
The company's shares slipped past 1% in recent Monday trade.
Price (AUD): $0.41, Change: $-0.01, Percent Change: -1.20%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。